Edition:
United Kingdom

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

29.66USD
19 Nov 2018
Change (% chg)

-- (--)
Prev Close
$29.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
97,482
52-wk High
$40.60
52-wk Low
$15.24

Latest Key Developments (Source: Significant Developments)

Akcea And Ionis Receive FDA Approval Of Tegsedi (Inotersen) For The Treatment Of The Polyneuropathy Of Hereditary Transthyretin-Mediated Amyloidosis In Adults
Friday, 5 Oct 2018 

Oct 5 (Reuters) - Akcea Therapeutics Inc ::AKCEA AND IONIS RECEIVE FDA APPROVAL OF TEGSEDI (INOTERSEN) FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS.AKCEA THERAPEUTICS INC - TEGSEDI IS NOW APPROVED IN U.S., EUROPEAN UNION AND CANADA.  Full Article

Akcea Therapeutics Inc QTRLY Net Loss Per Share Of Common Stock Was $0.72
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Akcea Therapeutics Inc ::AKCEA REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR SECOND QUARTER 2018.AKCEA THERAPEUTICS INC QTRLY RESEARCH AND DEVELOPMENT REVENUE $18.3 MILLION VERSUS $5.7 MILLION.AKCEA THERAPEUTICS INC QTRLY NET LOSS PER SHARE OF COMMON STOCK [OWNED BY IONIS] WAS $0.72.AKCEA THERAPEUTICS INC QTRLY NET LOSS PER SHARE OF COMMON STOCK [OWNED BY OTHERS] WAS $0.85.  Full Article

Akcea Therapeutics, PTC Therapeutics Collaborate To Commercialize Two Rare Disease Drugs In Latin America
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Akcea Therapeutics Inc ::AKCEA THERAPEUTICS AND PTC THERAPEUTICS COLLABORATE TO COMMERCIALIZE TWO RARE DISEASE DRUGS IN LATIN AMERICA.AKCEA THERAPEUTICS - PTC TO COMMERCIALIZE 2 OF CO'S RARE DISEASE DRUGS IN LATAM: TEGSEDI (INOTERSEN) AND WAYLIVRA (VOLANESORSEN).AKCEA THERAPEUTICS INC - PTC WILL GAIN EXCLUSIVE RIGHTS TO TEGSEDI AND WAYLIVRA IN LATIN AMERICA AND CERTAIN CARIBBEAN COUNTRIES.AKCEA THERAPEUTICS INC - PTC WILL PAY AKCEA AN UPFRONT LICENSING FEE OF $18 MILLION, $12 MILLION.AKCEA THERAPEUTICS INC - UPFRONT LICENSING FEE IS DUE ON SIGNING AND $6 MILLION WHICH WILL BE PAID ON EARLIER OF FDA OR EMA APPROVAL OF WAYLIVRA.AKCEA THERAPEUTICS INC - PTC WILL PAY AKCEA REGULATORY MILESTONES IN PTC TERRITORY UP TO A TOTAL OF $8 MILLION.AKCEA THERAPEUTICS INC - CO IS ALSO ELIGIBLE TO RECEIVE ROYALTIES FROM PTC IN MID-TWENTY PERCENT RANGE ON NET SALES OF EACH DRUG IN PTC TERRITORY.AKCEA THERAPEUTICS INC - COLLABORATION WILL BE GOVERNED BY A JOINT STEERING COMMITTEE WITH REPRESENTATION FROM BOTH PARTIES.  Full Article

Akcea And Ionis Announce Approval Of Tegsedi In The EU
Wednesday, 11 Jul 2018 

July 11 (Reuters) - Akcea Therapeutics Inc ::AKCEA AND IONIS ANNOUNCE APPROVAL OF TEGSEDI™ (INOTERSEN) IN THE EUROPEAN UNION.AKCEA THERAPEUTICS INC - TEGSEDI'S U.S. PRESCRIPTION DRUG USER FEE ACT, OR PDUFA, DATE IS OCTOBER 6, 2018.  Full Article

Akcea Initiates Phase 2b Study Of Hypertriglyceridemia And Established Heart Disease Treatment
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Akcea Therapeutics Inc ::AKCEA INITIATES PHASE 2B STUDY OF AKCEA-APOCIII-LRX IN PATIENTS WITH HYPERTRIGLYCERIDEMIA AND ESTABLISHED CARDIOVASCULAR DISEASE.AKCEA THERAPEUTICS INC - ‍ ANTICIPATES REPORTING TOP-LINE DATA FROM PHASE 2B OF AKCEA-APOCIII-L(RX)​ STUDY IN 2019.  Full Article

Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Akcea Therapeutics Inc :Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS.Akcea Therapeutics Inc - ‍in U.S., Food And Drug Administration assigned a prescription drug user fee act goal date of August 30, 2018​.Akcea Therapeutics Inc - marketing applications for Volanesorsen been accepted for review in U.S., EU & Canada for treatment of patients with FCS.  Full Article

Akcea initiates AKCEA-ANGPTL3-LRx Phase 2 program in patients with rare hyperlipidemias
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Akcea Therapeutics Inc :Akcea initiates AKCEA-ANGPTL3-LRx Phase 2 program in patients with rare hyperlipidemias.Akcea Therapeutics Inc - ‍AKCEA-ANGPTl3-L(Rx )is designed to reduce production of angiopoietin-like 3, or ANGPTL3​.  Full Article

Akcea Therapeutics Q3 loss per share $0.27
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Akcea Therapeutics Inc :Q3 loss per share $0.27.Akcea Therapeutics Inc qtrly ‍revenue $13.4 million​.Q3 earnings per share view $-0.19, revenue view $11.9 million -- Thomson Reuters I/B/E/S.  Full Article

Akcea Therapeutics genetic disease treatment gets FDA approval

Oct 5 Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration.